High concordance between nonalcoholic fatty liver disease and metabolic dysfunction associated steatotic liver disease in the TARGET-NASH real world cohort

A Sidney Barritt 4th; Feng Yu; Andrea R Mospan; Philip Newsome; Michael Roden; Heather L Morris; Rohit Loomba; Brent A Neuschwander-Tetri; TARGET-NASH investigators

doi:10.14309/ajg.0000000000002796

High concordance between nonalcoholic fatty liver disease and metabolic dysfunction associated steatotic liver disease in the TARGET-NASH real world cohort

Am J Gastroenterol. 2024 Apr 8. doi: 10.14309/ajg.0000000000002796. Online ahead of print.

Authors

A Sidney Barritt 4th¹, Feng Yu², Andrea R Mospan², Philip Newsome³, Michael Roden⁴, Heather L Morris², Rohit Loomba⁵, Brent A Neuschwander-Tetri⁶; TARGET-NASH investigators

Affiliations

¹ UNC Liver Center, University of North Carolina, Chapel Hill, NC.
² Target RWE, Durham, NC.
³ University of Birmingham, Birmingham, UK.
⁴ German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Dusseldorf.
⁵ Division of Gastroenterology, Department of Medicine, University of California at San Diego, CA.
⁶ Division of Gastroenterology and Hepatology, Saint Louis University.

PMID: 38587293
DOI: 10.14309/ajg.0000000000002796

Abstract

Introduction: This study investigates the applicability of the new MASLD nomenclature to the real-world TARGET-NASH US adult cohort.

Methods: The new MASLD/MASH nomenclature was applied to patients enrolled with pragmatic diagnoses of NAFL, NASH and NASH cirrhosis and concordance was determined between the definitions.

Results: 99% of TARGET-NASH participants met the new MASLD diagnostic criteria. 1484/1541 (96.3%, kappa 0.974) NAFL patients (MASL), 2195/2201 (99.7%, kappa 0.998) NASH patients (MASH), and 1999/2003 (99.8%, kappa 0.999) NASH cirrhosis patients met the new criteria.

Conclusion: The new MASLD nomenclature is highly concordant with the prior TARGET-NASH pragmatic definitions.

Grants and funding

Target RWE